Zevra Therapeutics Inc.

7.33
-0.16 (-2.14%)
At close: Apr 01, 2025, 3:59 PM
7.38
0.68%
After-hours: Apr 01, 2025, 07:55 PM EDT

Zevra Therapeutics Statistics

Share Statistics

Zevra Therapeutics has 54.12M shares outstanding. The number of shares has increased by 29.3% in one year.

Shares Outstanding 54.12M
Shares Change (YoY) 29.3%
Shares Change (QoQ) 1.39%
Owned by Institutions (%) 70.89%
Shares Floating 53.53M
Failed to Deliver (FTD) Shares 14.85K
FTD / Avg. Volume 3.44%

Short Selling Information

The latest short interest is 5.47M, so 10.25% of the outstanding shares have been sold short.

Short Interest 5.47M
Short % of Shares Out 10.25%
Short % of Float 10.31%
Short Ratio (days to cover) 10.4

Valuation Ratios

The PE ratio is undefined and the forward PE ratio is -196.75. Zevra Therapeutics's PEG ratio is undefined.

PE Ratio undefined
Forward PE -196.75
PS Ratio 16.34
Forward PS 1.1
PB Ratio 9.72
P/FCF Ratio undefined
PEG Ratio undefined
Financial Ratio History

Enterprise Valuation

Zevra Therapeutics Inc. has an Enterprise Value (EV) of 232.93M.

EV / Earnings -2.21
EV / Sales 9.86
EV / EBITDA -3.05
EV / EBIT -2.68
EV / FCF -3.34

Financial Position

The company has a current ratio of 2.53, with a Debt / Equity ratio of undefined.

Current Ratio 2.53
Quick Ratio 2.47
Debt / Equity undefined
Total Debt / Capitalization 60.32
Cash Flow / Debt -1.16
Interest Coverage undefined

Financial Efficiency

Return on equity (ROE) is -2.66% and return on capital (ROIC) is -101.88%.

Return on Equity (ROE) -2.66%
Return on Assets (ROA) -0.59%
Return on Capital (ROIC) -101.88%
Revenue Per Employee $400,203.39
Profits Per Employee $-1,788,322.03
Employee Count 59
Asset Turnover 0.13
Inventory Turnover 3.76

Taxes

Income Tax 15.37M
Effective Tax Rate -0.17

Stock Price Statistics

The stock price has increased by 45.35% in the last 52 weeks. The beta is 1.98, so Zevra Therapeutics's price volatility has been higher than the market average.

Beta 1.98
52-Week Price Change 45.35%
50-Day Moving Average 7.89
200-Day Moving Average 7.56
Relative Strength Index (RSI) 40.3
Average Volume (20 Days) 431.39K

Income Statement

In the last 12 months, Zevra Therapeutics had revenue of 23.61M and earned -105.51M in profits. Earnings per share was -2.28.

Revenue 23.61M
Gross Profit 16.2M
Operating Income -87M
Net Income -105.51M
EBITDA -76.4M
EBIT -87M
Earnings Per Share (EPS) -2.28
Full Income Statement

Balance Sheet

The company has 33.78M in cash and 60.3M in debt, giving a net cash position of -26.51M.

Cash & Cash Equivalents 33.78M
Total Debt 60.3M
Net Cash -26.51M
Retained Earnings -505.29M
Total Assets 178.13M
Working Capital 51.96M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -69.67M and capital expenditures 0, giving a free cash flow of -69.67M.

Operating Cash Flow -69.67M
Capital Expenditures 0
Free Cash Flow -69.67M
FCF Per Share -1.51
Full Cash Flow Statement

Margins

Gross margin is 68.59%, with operating and profit margins of -368.47% and -446.85%.

Gross Margin 68.59%
Operating Margin -368.47%
Pretax Margin -381.76%
Profit Margin -446.85%
EBITDA Margin -323.56%
EBIT Margin -368.47%
FCF Margin -295.04%

Dividends & Yields

ZVRA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -30.4%
FCF Yield -17.15%
Dividend Details

Analyst Forecast

The average price target for ZVRA is $21.5, which is 186.7% higher than the current price. The consensus rating is "Strong Buy".

Price Target $21.5
Price Target Difference 186.7%
Analyst Consensus Strong Buy
Analyst Count 8
Stock Forecasts

Stock Splits

The last stock split was on Dec 28, 2020. It was a backward split with a ratio of 1:16.

Last Split Date Dec 28, 2020
Split Type backward
Split Ratio 1:16

Scores

Altman Z-Score -3.16
Piotroski F-Score 3